Baseline Quantitative CT Predicts Rate of Decline in Forced Vital Capacity and Clinically Relevant Outcomes in Patients With Progressive Pulmonary Fibrosis: Results from the INBUILD Trial
作者
Peter M. George,Carina Ittrich,Anand Devaraj,Eric S. White,Jonathan Gerald Goldin,Olivier Joly,Susanne Stowasser,Frank Risse
Abstract Rationale: In the placebo-controlled INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in subjects with progressive pulmonary fibrosis (PPF). We used standardized non-contrast high resolution computed tomography (HRCT) data to investigate the potential of two separate quantitative imaging analysis methods to prognosticate subsequent rate of decline in FVC and time-to-event timepoints. Methods: Subjects had an ILD other than idiopathic pulmonary fibrosis and an extent of fibrosis on HRCT >10%. HRCT scans acquired within 85 days of start of treatment were defined as baseline scans. In the placebo group, we analyzed quantitative extent of interstitial lung disease (QILD) using an established quantitative CT method and total disease extent (TDE), weighted reticulovascular score (WRVS) using Brainomix e-Lung. Analyses of prognostic potential of continuous baseline quantitative CT assessments for rate of decline over 52 weeks in FVC [mL/year] were based on a random coefficient regression model. The prognostic potential of dichotomized baseline quantitative CT assessments for time-to-death and the composite of time-to-death or absolute decline in FVC % predicted >10% as a measure of disease progression were analyzed using Cox regression models. Median values of quantitative CT parameters at baseline were used as cut-offs. Results: 257 subjects in the placebo group had QILD scores and 192 had TDE and WRVS at baseline. Estimates for the rate of decline in FVC are presented in the table. Subjects with ≥34.0% extent of QILD or ≥20.9% TDE had a significantly increased risk (HR 2.14 (1.40, 3.28), p=0.0004 and HR 1.87 (1.16, 3.01), p=0.0105, respectively) of disease progression within one year. Using these same cutoffs, subjects had a significantly increased risk (HR 3.22 (1.57, 6.58), p=0.0014 and HR 3.50 (1.44, 8.47), p=0.0056) of death over the whole trial. Subjects with a median WRVS of 14.9% had a significantly increased risk of disease progression within one year as well as a significantly increased risk of mortality during the trial (HR=2.10 (1.28, 3.45), p=0.0034 and HR=2.90 (1.14, 7.37), p=0.0256). Conclusion: Quantitative CT, independent of the method used, was able to predict the rate of decline in FVC over 52 weeks and time-to-disease progression or death based on the single point estimate of percentage of lung affected at baseline in a PPF study population. These results encourage the application of quantitative CT in routine clinical practice for prognostic use as well as in clinical trials for patient selection.